tirzepatide patent expiration eli lilly FDA approves Lilly's for weight loss Mounjaro, Zepbound: Generic GLP-1 Drugs

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine In 3,297 patients with T2D, semaglutide reduced major adverse cardiovascular events by 26% versus placebo over 2.1 years (HR 0.74), driven by 39% stroke reduction and 26% nonfatal MI reduction

NEJM Full Text Jastreboff, A.M., et al

These findings were also dose-dependent, with 3 g/10 mL/kg demonstrating more potent food suppression than 1 g/10 mL/kg

Part Nine: Generic Industry Economics Post-Expiry The Generic Manufacturers Business Model The economics of generic pharmaceutical manufacturing are unlike those of innovator drug development in almost every dimension

Lawrence Review of Natural Products Aug 1993 (monograph)